- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Single-inhaler triple treatment for COPD lowers exacerbation and mortality in COPD patients
![Single-inhaler triple treatment for COPD lowers exacerbation and mortality in COPD patients Single-inhaler triple treatment for COPD lowers exacerbation and mortality in COPD patients](https://medicaldialogues.in/h-upload/2021/04/13/750x450_151208-inhaler.webp)
In a new study conducted by Bernardino Alcázar-Navarrete and colleagues, it was found that COPD patients who started Single-inhaler triple therapy (SITT) showed a clinically meaningful improvement in persistence, which decreased mortality, the occurrence of exacerbations, and the utilization of healthcare resources, all of which resulted in a mean cost savings. The findings of this study were published in the Chest Journal.
Chronic obstructive pulmonary disease (COPD) is a leading contributor to mortality and disability. Reducing exacerbations and enhancing symptom management are two objectives of COPD treatment. Patients who experience frequent exacerbations despite receiving bronchodilator medication should get either single-inhaler triple therapy (SITT) or multiple-inhaler triple therapy (MITT). In terms of treatment persistence, exacerbations, and other outcomes, there is presently no information contrasting SITT to MITT in Spain. This study was carried out in order to determine if COPD patients in Spain commencing SITT or MITT have improved persistence, exacerbations, and healthcare resource consumption.
This observational, retrospective, real-world cohort analysis identified COPD patients aged 40 years beginning SITT or MITT (using two or three inhalers) between June 1, 2018, and December 31, 2019, by examining electronic health records in the Spanish National Healthcare System BIG-PAC® database. During a 12-month follow-up, comparative data on persistence (allowing up to 60 days without a medication refill), exacerbation rates, healthcare resource consumption, and expenditures were examined. Analyses with many variables were conducted.
The key findings of this study were as follow:
1. The mean age of the eligible patients (n=4625) commencing SITT (n=1011) or MITT (n=3614) was 70.9 years; the majority (73.9%) were men; and the majority of them had moderate (62.0%) or severe (26.5%) airflow limitations.
2. Baseline traits between cohorts were comparable.
3. In comparison to MITT patients, SITT patients exhibited higher persistence, a lower risk of exacerbations, and a decreased risk of all-cause death at the 12-month follow-up.
4. SITT was linked to a greatly reduced utilization of healthcare resources.
5. Persistence was linked to lower exacerbation rates compared to non-persistence for SITT and MITT, as well as significant adjusted MACS.
Reference:
Alcázar-Navarrete, B., Jamart, L., Sánchez-Covisa, J., Juárez, M., Graefenhain, R., & Sicras-Mainar, A. (2022). Clinical characteristics, treatment persistence and outcomes among patients with COPD treated with single- or multiple-inhaler triple therapy: a retrospective analysis in Spain. In Chest. Elsevier BV. https://doi.org/10.1016/j.chest.2022.06.033
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751